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Abstract
Background: Neoadjuvant fluoropirimidine (5FU)-based chemoradiotherapy (CRT) has been considered the standard
of care for locally advanced rectal cancer (LARC). Whether addition of oxaliplatin (OXP) will further improve clinical
outcomes is still debated. We conducted a meta-analysis to evaluate the role of OXP in this patient population.
Methods: Literature searches were carried out in PubMed, Medline and Scopus databases. End points were overall
survival (OS), disease free survival (DFS), local failure (LF) and distant failure (DF). Odd ratio (OR) with 95% confidence
interval (CI) was calculated using random effects model.
Results: Four randomized trials were included. Patients treated with OXP-5FU CRT had significantly decreased DF
(OR = 0.76; 95% CI, 0.60 to 0.97; p = 0.03) compared to standard CRT. OS, DFS and LF were not significantly different
between groups.
Conclusions: OXP significantly decreased DF, but does not improve OS e DFS compared to 5FU CRT. Precise role of
OXP in neoadjuvant setting of LARC remains to be determined.
Keywords: Locally advanced rectal cancer, Oxaliplatin, Fluoruracil, Neoadjuvant treatment, Chemoradiotherapy,
Survival, Distant metastasis
Background
The treatment of locally advanced rectal cancer (LARC)
is multidisciplinary and it is developed from clinical
trials evidence [1–4]. The trimodality approach, includ-
ing neoadjuvant 5-fluorouracil (5FU)-based chemora-
diotherapy (CRT), surgery and adjuvant chemotherapy,
is considered the standard of care in this setting of pa-
tients [5]. Despite improvement in surgical techniques
as well as advances in radiation therapy techniques and
chemotherapeutic agents, nowadays the vast majority of
recurrences in LARC are systemic [6]. Distant metastasis
rate remains high (approximately 40%) and becomes the
prevailing method of treatment failure.
Based on the efficacy demonstrated in colon cancer
trials, the intensification regimen with oxaliplatin (OXP)
as radiation-sensitizing agent in neoadjuvant CRT has
been tested in several large phase III studies – STAR-01,
ACCORD 12, NSAPB R-04, CAO/ARO/AIO- 04 and
Chinese trial – but definitive conclusions are still pend-
ing [7–11].
Recently update of results have been presented and in
light of these data we performed a meta-analysis. The
aim of this meta-analysis was to evaluate whether the
addition of OXP in neoadjuvant treatment for LARC
could be superior to standard CRT, in term of overall
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survival (OS), disease free survival (DFS), local failure
(LF) and distant failure (DF).
Methods
Selection of trials
The preferred reporting items for systematic reviews and
meta-analyses (PRISMA) guidelines were followed to
perform search strategy and selection processes. The
meta-analysis included trials, written in English, without
any restrictions on publication date. The last search was
carried out on May 2016. Systematic literature electronic
search was conducted in Pubmed, Medline and Scopus
databases. The search term used were “radiotherapy”,
“chemoradiotherapy”, “chemotherapy”, “oxaliplatin/OXP”,
“fluorouracil/5FU/fluoropyrimidine”, “capecitabine/xeloda”,
“rectal cancer/locally advanced rectal cancer”, “neoadju-
vant”, “randomized” and “clinical trials” in the title.
To be eligible for this meta-analysis, trials needed to
compare the addition of OXP to neoadjuvant CRT with
standard 5FU-based CRT in LARC. To reduce publica-
tion bias, data from all clinical randomized trials, both
abstract and full-text paper, were included using litera-
ture electronic databases searching (Pubmed, Medline
and Scopus) and hand searching (meeting proceedings
of European Society for Radiotherapy & Oncology,
European Society of Medical Oncology and American
Society of Clinical Oncology). Reference lists of previ-
ously published reviews and meta-analysis were ex-
plored to identify relevant citations. Trials were eligible
if participants were newly diagnosed, with histologically
proven adenocarcinoma of the rectum at study entry.
In closer evaluation of potentially eligible articles, when
two articles appeared to report results with overlapping
data, only the data representing the most recent publi-
cation were included in the meta-analysis.
Data extraction
Extracted data were recorded into standardized database
according to the following parameters: first author’s sur-
name, year of publication, trial acronym, sample size of
experimental and standard group, chemotherapy regi-
men, drug and dosage, radiotherapy total dose and single
fraction.
Endpoints
The intent of the analysis was to evaluate disease free
survival (DFS), overall survival (OS), local failure (LF)
and distant failure (DF). DFS was defined as the time
from the date of randomization to last follow-up, death
or disease progression. OS was defined as the time from
the date of randomization to last follow-up or death. LF
was defined as the time from random assignment to
local recurrence within the pelvis. DF was defined as the
time from random assignment to distant metastasis
occurrence, irrespective of whether this was a first event
or not.
The number of events (death, progression and distant
metastasis), when available, were derived from each
study. At least one of these two outcomes should have
been assessed and reported in the trial to be included in
the present analysis.
Statistical analysis
Statistical analysis was performed using Review Manager
5.0 (http://www.cochrane.org). It was based on both
abstract (thus analysis of the full-text results was not
performed) and full-text paper results. The analysis used
odds ratio (OR) to compare results for OXP-5FU group
to control patients. The pooled OR was calculated using
a random-effects model. Forest plots were used for
graphical representation of each study and pooled ana-
lysis. OR, variance, 95% confidence interval (CI), log
[risk ratio] and standard error for each study were calcu-
lated, based on Tierney et al. method [12]. A significant
two-way p value for comparison was defined as p < 0.05.
Statistical heterogeneity between studies was investi-
gated using Cochrane Q statistic (significant at p < 0.1)
and the I2 value (significant heterogeneity if >50%) [13].
Publication bias was examined using Egger et al. [14]
and Begg et al. [15] analyses.
Results
Search results
Four trials (3310 patients) were identified through the lit-
erature search that fulfilled the inclusion criteria (Fig. 1).
Two trials were undertaken in Europe, one in USA and
one in China. Baseline characteristics of these studies are
outlined in Table 1. In total, 1650 patients received OXP-
5FU CRT and 1660 patients were randomized to 5FU
CRT. Patient characteristics, including age, gender and
clinical stage disease, were well balanced between groups
in all trials. In the ACCORD 12/0405-Prodige 2 trial, 509
patients were staged cT3 and 416 cases had positive





3020 articles excluded because no 
clinical trials
418 excluded because different 
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1 excluded because no extractable 
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Fig. 1 Flowchart for included and excluded trials
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in the German CAO/ARO/AIO-04 trial, 1071 patients
were staged cT3 and 892 patients with positive lymph
nodes. Baseline characteristics of patients from NSABP R-
04 study were classified as stage II (T3-4 N0) in 61.7% of
cases. Whereas, in the Chinese trial, a total of 127 patients
had cT3 disease and the vast majority of patients (161)
had positive lymph nodes.
Overall survival
All trials were included in this analysis. A total of 567
deaths were recorded. No difference in OS was observed
between the groups (OR = 0.84; 95% CI, 0.70 to 1.01;
p = 0.06). No heterogeneity was observed between trials
(I2 = 0%; χ2 test for heterogeneity, p = 0.79). Details are
shown in Fig. 2.
Disease free survival
The DFS analysis was based on all studies. A significant
difference was not observed in favor of adding OXP to
standard neoadjuvant CRT regimen (OR = 0.97; 95% CI
0.72 to 1.30; p = 0.83). The I2 value showed high hetero-
geneity (70%) among the studies (χ2 test for heterogen-
eity, p = 0.02) (Fig. 3).
Local failure
Among the four trials analyzed, the addition of OXP was
not associated with significant lower rate of local failures
than 5FU alone, with an OR of 0.76 (95% CI 0.55 to
1.06; p = 0.11). There was not a significant heterogen-
eity, with an I2 value of 29% (χ2 test for heterogeneity,
p = 0.24) (Fig. 4).
Distant failure
Data on DF were available for three trials – CAO/ARO/
AIO-04 [16], ACCORD 12 [17] and Chinese Study [11]
–. Thus DF analysis was conducted on a total of 2026
patients. OXP plus 5FU CRT was associated with a
lower rate of distant failures than standard CRT, with an
OR of 0.76 (95% CI, 0.60 to 0.97; p = 0.03). There was
no evidence of significant statistical heterogeneity be-
tween trials (I2 18%; χ2 test for heterogeneity, p = 0.30)
(Fig. 5).
Discussion
We performed a meta-analysis to compare the efficacy
of neoadjuvant CRT with OXP plus 5FU to 5FU alone in
LARC. The main result of this meta-analysis was that
addition of OXP to standard 5FU-based CRT was related
to significant clinical benefit in term of DF. Whereas,
Table 1 Baseline characteristics of trials
Trial Analyzed patients Schedule End point
Name Phase Year Total Per arm Regimen Drug and dose primary secondary
ACCORD12/0405
-Prodige 2
III 2010 584 291 OXP-5FU CRT Cap 1600 mg/mq daily + OXP 50 mg/mq weekly pCR CRM, SP, LC,PFS
293 5FU CRT Cap 1600 mg/mq daily
NSAPB R-04 III 2005 1284 643 OXP-5FU CRT 5FU 225 mg/mq daily or Cap 1650 mg/mq daily
+ OXP 50 mg/mq weekly
LRC OS, DFS, TLRR
641 5FU CRT 5FU 225 mg/mq daily or Cap 1650 mg/mq daily
CAO/ARO/AIO-04 III 2006 1236 613 OXP-5FU CRT 5FU 250 mg/mq days 1–14 and 22–35 + OXP
50 mg/mq on days 1,8,22,29
DFS
623 5FU CRT 5FU 1000 mg/mq days 1–5 and 29–33
Chinese study III 2007 206 103 OXP-5FU CRT Cap 1600 mg/mq days 1–14 and 22–25 + OXP
60 mg/mq on days 1,8,22,29
DFS, OS
103 5FU CRT Cap 1600 mg/mq days 1–14 and 22–25
OXP Oxaliplatin, 5FU 5-fluorouracil, CRT chemoradiotherapy, Cap Capecitabine, pCR pathologic complete response, CRM circumferential rectal margin, SP sphincter
preservation, LC local control, PFS progression-free survival, LRC loco-regional control; OS overall survival, DFS disease-free survival, TLRR time to
loco-regional recurrence
Fig. 2 Overall survival
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there was no significant increase in OS, as well as no
lower DFS and LF rates were observed between groups,
although globally a higher proportion of events was re-
corded in patients treated with standard CRT.
Nowadays, the treatment of LARC is multidisciplinary
and it is developed from clinical trials evidence. The tri-
modality approach, including neoadjuvant CRT, total
mesorectal excision surgery and adjuvant chemotherapy,
represents the standard of care in this setting of patients,
due to its value to improve local control up to 90% of
cases [18]. However it does not decrease distant failures
and year after year the concept of intensify treatment
regimen has become progressively more common in
order to improve systemic control. Based on the efficacy
demonstrated in colon cancer patients [19], OXP-based
intensification of neoadjuvant CRT has been tested in
several randomized trials and, recently, a meta-analysis
has evaluated its short term efficacy and toxicity results
[20]. Briefly, OXP-5FU regimen increased pathologic
complete response (OR = 1.20; 95% CI, 1.01 to 1.42) and
reduced peri-operative metastasis incidence (OR = 0.51;
95% CI, 0.34 to 0.77), but increased severe toxicity rate
(OR = 2.29; 95% CI, 1.31 to 4.0) compared to 5FU alone.
Given these results, the clinical outcomes analysis
plays an important role in the treatment decision. Only
one randomized trial demonstrated a survival benefit
following addition of OXP, whereas the others failed to
demonstrate it [9, 11, 16, 17]. On this background, we
performed a meta-analysis to investigate the important
question of identifying the optimal concomitant chemo-
therapy regimen to use in neoadjuvant CRT treatment
in LARC. No clear evidenced resulted in prolonging OS
(OR = 0.84; 95% CI, 0.70 to 1.01) and DFS (OR = 0.97;
95% CI 0.72 to 1.30) compared with the standard CRT.
But OXP patients had a 24% risk reduction of developed
distant metastasis (p = 0.03) than patients treated with
single agent CRT.
There are several considerations that should be made,
because the trials included in the meta-analysis did not
address exactly the same end-points, and treatments
were not exactly similar.
The tested primary end-points were DFS in CAO/
ARO/AIO-04 trial [8], DFS and OS in Chinese trial [11],
pathologic complete response in ACCORD 12 trial [7]
and loco-regional control in NSAPB R-04 trial [9]. These
different primary endpoints delineated the lack of statis-
tical power to assess the chosen endpoints. Considering
that the vast majority of recurrences in LARC remain
systemic, the theoretical advantage of adding OXP to
standard CRT should be primarily to improve distant
control. Thus, a DF analysis was performed. Based on
this analysis, it is possible to hypothesize that the
addition of OXP is an efficient regimen to reduce the
risk of systemic metastasis in LARC (OR: 0.76; 95% CI,
0.60 to 0.97). The limitations of the analysis are related
to the relative limited number of trials and the hetero-
geneity of primary end-points. In fact, one trial had no
data on distant failure [9]. Moreover it should be noted
that DFS was considered the primary end-point in two
out of three trials included, and it maybe has reduced
the power of the analysis, but do not bias it. In addition
studies were conducted in different countries and prob-
ably quality of care might have influenced the results.
Indeed these trials included different surgical approach
details, such as number of examined lymph nodes and
type of surgery. Total mesorectal excision was per-
formed in the vast majority of cases. Other types of sur-
gery, including Hartmann procedure, intersphincteric
Fig. 3 Disease free survival
Fig. 4 Local failure
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resection, transanal local excision or low anterior resec-
tion were also recorded. But the absence of complete
surgical data prevents from defining a specific popula-
tion that would or would not benefit from OXP-5FU
regimen. Thus whether the inclusion of OXP into 5FU-
based CRT could reflect the new treatment option for
patients with LARC cannot be resolved by our meta-
analysis. Surely, the benefit of adding OXP on DF could
justify the proven substantial increase in acute toxicity,
especially severe diarrhea [20]. Among the trials in-
cluded, patients received substantially similar OXP regi-
mens – 50 mg/m2 once a week or 60 mg/m2 on days 1,
8, 22, 29 – but heterogeneous 5FU schedule. In CAO/
ARO/AIO-04 trial [8], the 5FU schedules even differed
in the two treatment groups – 250 mg/m2 daily in ex-
perimental group versus 1000 mg/m2 weeks 1 and 5 of
RT in control group –, whereas the other trials used the
same 5FU regimen for both treatment – 225 mg/m2
daily or 1600 mg/m2 daily – [7, 9, 11]. Considering that
5FU is probably the main responsible for gastrointestinal
toxicity, including diarrhea, nausea and vomiting, we
believe that acute toxicity could be easily minimize by
decrease the individual 5FU doses (200 mg/m2) and in-
crease the frequency of administration of weekly OXP
(to a maximal total dose of 300 mg), maintaining thera-
peutic effectiveness [21]. In our published retrospective
analysis, we found a considerable decrease in toxicity
(17%), particularly in terms of severe diarrhea (4%) com-
pared to grade 3/4 toxicity rate reported in randomized
studies, ranged from 21.4% to 41.9% [7–11].
To our knowledge, this is the first meta-analysis with
long-term follow-up data to show a DF benefit of adding
OXP to 5FU-based CRT when compared with standard
treatment with 5FU alone for patients with LARC. How-
ever results need to be interpreted with caution, because
it is an abstract-based meta-analysis. Although abstract
included statistical quality details, definitive full-text re-
sults could improve data analysis precision and produce
more robust conclusions. In particular, subgroup analysis
might reveal different results for some patients, such as
node positive versus node negative patients. However,
reduction in DF could be considered a sensible result,
reflecting itself a relevant benefit for patients, regardless
of survival improvement.
Conclusions
Adding OXP to standard CRT had significant effect on
distant metastasis control, however no survival benefit
was derived. Further data are needed to clarify the pre-
cise role of OXP in neoadjuvant setting of LARC.
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